Answers are grounded in this paper and cite their sources.
The frequency of lipodystrophy in cross-sectional studies in chronic HIV-infected patients treated with highly active antiretroviral therapy (HAART) including a protease inhibitor (PI) varies between 2 and 84% according to the method of estimation (self-report or physical examination), whereas it is estimated as being between 0 and 4% in less numerous studies including patients with PI-sparing regimens [1]. Little is known about the incidence of lipodystrophy in patients treated early after seroconversion. Up to November 1999, 143 patients diagnosed during primary HIV-1 infection have been enrolled in the multicentre French PRIMO cohort [2]. Primary infection was assessed by an incomplete Western blot or a positive p24 antigenemia test with a negative or poor enzyme-linked immunosorbent assay. No patient had been given antiretroviral treatment before enrolment. The median delay from the estimated date of infection and initiation of HAART was 1.4 months. The 84 patients who were prescribed HAART during primary infection, with or without a PI, and who had been treated for at least 6 months, were included in this study. A physical examination (face, limbs, trunk, abdomen, breast, skin and nails) was performed regularly by the physicians using a scale of severity of abnormalities (0: none, 1: mild, 2: moderate, 3: severe). Most patients (88.0%) were prescribed triple therapy including a PI (44.6% indinavir; 28.4% ritonavir; 21.6% nelfinavir; and 5.4% saquinavir). The other patients received dual therapy (2.4%), triple therapy without a PI (6.0%), or more than three molecules in association (3.6%). After a mean follow-up of 18.9 months, 14 (16.7%) patients developed clinical lipodystrophy, defined as the presence of at least one clinical sign (Table 1). At 6 months after the initiation of therapy during primary infection the cumulative incidence of clinical lipodystrophy was 5%. It reached 9 and 26% at 12 and 24 months, respectively. The mean number of clinical signs was 1.8 (1–4) and the mean severity was 1.4 (1–2). The most frequent clinical sign was abdominal hypertrophy (64.3%), followed by limb wasting, Bichat fat pad atrophy, or breast hypertrophy (28.6%, respectively). No difference between lipodystrophic and non-lipodystrophic patients was found according to sexual preference, sex, age, mean follow-up, and mean total duration of treatment. Furthermore, we did not find any significant difference between the two groups according to the nucleoside analogue or the type of PI. At inclusion, the median number of CD4 cell counts was similar in the two groups. The median number of CD8 cell counts was significantly higher in lipodystrophic patients than in other patients. No difference was found between the two groups according to plasma HIV RNA at inclusion, but at the last visit plasma HIV RNA was lower in the lipodystrophic group, although the difference was of borderline significance (1.1 versus 1.5 log10 copies/ml;P = 0.12). Similarly, at the last follow-up visit, both median CD4 and CD8 cell counts were significantly higher in lipodystrophic patients than in the other patients (1087 versus 739 cells/μl;P = 0.02 and 1041 versus 727 cells/μl;P = 0.002, respectively). The increase in CD4 cell counts and the decrease in CD8 cell counts during follow-up were higher in the lipodystrophic patients compared with other patients, as was the decrease in plasma HIV RNA. No significant difference was found between the two groups according to adherence to treatment as quoted by the physicians. All 14 lipodystrophic patients had received a triple therapy including a PI as the initial treatment. In these latter patients, the levels of glucose, total cholesterol and HDL cholesterol measured before the diagnosis of lipodystrophy were similar to those measured at the time of diagnosis. Only the level of triglycerides was higher than before the diagnosis of lipodystrophy (3.08 versus 1.65 mmol/l;P = 0.07).Table 1: Characteristics of the 84 patients treated during primary HIV-1 infection according to the occurrence of lipodystrophy. In conclusion, we have observed that lipodystrophy can occur early after the initiation of HAART, even when patients are treated during primary infection. This finding is an argument against the sole role of the duration of HIV-1 infection in the pathogenesis of lipodystrophy. However, both the rate of occurrence of lipodystrophy and the degree of severity appear to be lower in this large study of primary-infected patients than in chronic patients who are antiretroviral therapy-naive at the time of HAART initiation. Our results strongly suggest that lipodystrophy is of multifactorial origin, one of the factors probably being the immunovirological response to treatment. Immunological analyses are therefore under way to provide a better understanding of this observation. Cécile Goujarda Faroudy Boufassab Christiane Deveaub Djamila Laskrib Laurence Meyerb for the PRIMO group
No takes yet. Share an insight, caveat, or question.
Goujard et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: